A phase I study of AZD2171 and Temsirolimus in patients with advanced gynecological malignancies.

Susana M CamposSuzanne BerlinCarolyn N KrasnerChristin WhalenTina AtkinsonKristin MeeganLauren PereiraKarin TyburskiWeixiu LouHang LeeNeil HorowitzRichard T Penson

Published in: Cancer chemotherapy and pharmacology (2022)

Despite a conservative dose escalation, the toxicity data demonstrated that the combination of AZD2171 and Temsirolimus was not tolerable. Increased awareness of novel toxicities, pharmacological interactions, coupled with strict patient selection and early mitigation of side effects may enhance phase I clinical trial development.

Keyphrases

clinical trial
open label
climate change
oxidative stress
randomized controlled trial
study protocol
machine learning
double blind